Receive our newsletter – data, insights and analysis delivered to you
July 13, 2009

US Senate Moves to Protect Biotech Drugs

A US Senate Committee has approved an amendment to protect manufacturers of biotechnology drug products from generic competition for 12 years. A 16-7 vote in the Senate Health, Education, Labor and Pensions Committee approved the amendment to award the biotechnology industry with 12 years

By cms admin

A US Senate Committee has approved an amendment to protect manufacturers of biotechnology drug products from generic competition for 12 years.

A 16-7 vote in the Senate Health, Education, Labor and Pensions Committee approved the amendment to award the biotechnology industry with 12 years of exclusivity before generics can be launched.

Biotech medicines, or biologics, are manufactured from living cells. Despite being more complicated and expensive to produce than conventional drugs they represent a growing segment of the industry.

Generic drug makers backed proposals limiting the exclusivity of the period from five to seven years.

The amendment now faces Congress, where it expects a tough challenge from supporters of a shorter exclusivity period.

Major manufacturers of biotech drugs include Amylin, Teva Pharmaceuticals and Mylan.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU